NeuroMab™ Anti-TNFR2 Antibody(NRP-0422-P777)

Product Overview

Description

The antagonistic TNFR2 antibody can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Human

Applications

ELISA; FC; In Vitro; Inhib; In Vivo; Antagonist

Relevant Diseases

Neuroinflammation

Product Properties

Formulation

PBS only

Preservatives

BSA Free

Concentration

1mg/mL

Purification

Purified recombinant IgG prepared by affinity chromatography on Protein A from a mammalian cell line

Purity

>95% by SDS PAGE or HPLC

Endotoxin Level

Regular Endotoxin < 5 EU/mg
Low Endotoxin < 1 EU/mg

Shipping

Gel Packs

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Research Use Only

For research use only

Target

TNFR2

Official Name

TNFR2

Full Name

Tumor necrosis factor receptor 2

Alternative Names

TNFRSF1B; CD120b; TBPII; TNF-R-II; TNF-R75; TNFBR; TNFR1B; TNFR2; TNFR80; p75; p75TNFR; tumor necrosis factor receptor superfamily member 1B; TNF receptor superfamily member 1B

Gene ID

7133(Human); 21938(Mouse); 156767(Rat)

Uniprot ID

P20333(Human); P25119(Mouse); Q80WY6(Rat)

Product Pictures

FuncS

Figure 1 shows the results of replicate experiments performed to determine the effect of TNFRAB2 on T-reg cell proliferation.

LIM1863 xenograft tumor growth curves during treatment with mAb avp6 3G9 (A), soluble TGFbRII-Fc-Ig fusion protein (▼) or vehicle PBS (■).

Inhib

Figure 2 is a graph showing the ability of TNFRAB1 and TNFRAB2 to generally inhibit T-reg cell proliferation.

LIM1863 xenograft tumor growth curves during treatment with mAb avp6 3G9 (A), soluble TGFbRII-Fc-Ig fusion protein (▼) or vehicle PBS (■).

FuncS

Figure 3 is a graph showing the effect of TNFRAB1 and TNFRAB2 on T-reg cell proliferation relative to the effect induced by IL-2 treatment.

LIM1863 xenograft tumor growth curves during treatment with mAb avp6 3G9 (A), soluble TGFbRII-Fc-Ig fusion protein (▼) or vehicle PBS (■).

FCM

Figure 4 Flow cytometry plot showing various phenotypes of the effects of drugs directing T-reg cell growth (eg, TNFα, IL-2, and TNFR2 agonists) and the TNFR2 antagonist TNFRAB2 on T-reg cell proliferation.

Treatment with a TNFR2 antagonist antibody preferentially inhibits the proliferation of CD25Hi-expressing T-reg cells. After incubation for up to 48 h with IL-2 (200 U/ml), TNFα (20 ng/ml), or TNFR2 antagonist antibody (12.5 pg/ml) alone, the proportion of CD4+, CD25Hi+ cells expressing TNFR2 is shown.